Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novoste (novt) -- Ignore unavailable to you. Want to Upgrade?

To: Zantac who wrote (58)	6/3/1999 9:41:00 PM
From: Oak Tree	Read Replies (1) \| Respond to of 100

I agree. News even at best is unlikely to immediately justify a value over 25. That is especially true since we know that they had to increase the study by 300 patients because of thrombosis (they lengthend the duration of anticoagulants). My guess that selling short could make some money right now. Buy back when its below 17 -- since ultimately thrombosis is preventable if it succeeds in preventing restenosis (as I believe it will from my own rat and pig studies).